Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELFIDENCE long-term study of elafibranor in adults with primary biliary cholangitis
2023-505251-43-00Phase 3Authorised
- Sponsor
- Ipsen
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Elafibranor 80 mg with Placebo (2 arms). Primary endpoint: Event-free survival. Planned start Feb 2024; status: authorised.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2023-505251-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505251-43-00.